两种药物治疗婴幼儿表浅型血管瘤的疗效及安全性分析

目的研究外用马来酸噻吗洛尔和口服普萘洛尔治疗婴幼儿表浅型血管瘤的疗效及安全性。方法将我院2017年10月~2018年4月收治的200例表浅型血管瘤婴幼儿患者分为外用组与内服组,各100例。外用组采用外用的马来酸噻吗洛尔溶液治疗,内服组采用口服普萘洛尔治疗,用药时间为12个月,每月定期进行复查,比较两组患儿治疗前后的疗效、血管瘤血流峰值(PSV)和阻力系数(RI),并监测副反应的情况。结果治疗后,外用组显效率为70%,内服组显效率为67%,治疗效果无显著性差异(P>0.05);治疗后,两组的PSV、RI均得到改善,无显著性差异(P>0.05);治疗后,外用组不良反应显著低于内服组(P<0.05),且两组均未出现严重不良反应。结论采用外用马来酸噻吗洛尔治疗婴幼儿表浅型血管瘤安全性比口服普萘洛尔安全性好,效果显著,不良反应少,值得推广使用。

Efficacy and Safety of Two Drugs in the Treatment of Superficial Hemangiomas in Infants

Objective To study the efficacy and safety of external application of timolol maleate and oral administration of propranolol in the treatment of superficial hemangiomas in infants.Methods 200 infants with superficial hemangiomas admitted to our hospital from Oct.2017 to Apr.2018 were divided into external application group and oral administration group,with 100 cases in each group.External application group was given external application of timolol maleate solution,and oral administration group was given oral administration of propranolol,and they were treated for 12 months,and were given monthly routine review.The efficacy,hemangioma peak blood flow(PSV)and resistance index(RI)were compared between the two groups before and after treatment,and the side reactions were monitored.Results After treatment,the marked effective rate was 70%in external application group and 67%in oral administration group,and there was no significant difference in the therapeutic effect(P>0.05).After treatment,the PSV and RI in the two groups were improved(P>0.05).After treatment,the rate of adverse reactions in external application group was significantly lower than that in oral administration group(P<0.05),and there were no serious adverse reactions in the two groups.Conclusion External application of timolol maleate for superficial hemangiomas in infants has better safety,more significant effects and fewer adverse reactions than oral administration of propranolol.Thus it is worthy of promotion and application.